Gavin B. Samuels

Consumer Services

Health Technology

Profile

Gavin B.
Samuels is Senior Vice President of Business Development for Quark Pharmaceuticals, Inc. Prior to joining Quark Pharmaceuticals March, 2007 he held several positions at Worldwide Business Development and Worldwide Product Development Groups for Pfizer, Inc. Previously, he was Senior Associate of Healthcare Strategy and Corporate Affairs for Merck Sharpe & Dohme in Australia.
Dr. Samuels received an MS from the University of Witwatersrand, an MBA from the University of New England (Australia) and a degree in Health Economics from Monash University, Australia.

Former positions of Gavin B. Samuels

Companies	Position	End
Quark Pharmaceuticals, Inc. Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA.	Corporate Officer/Principal	2010-09-22
PFIZER, INC.	Corporate Officer/Principal	-

See the detail of Gavin B. Samuels's experience

Training of Gavin B. Samuels

University of the Witwatersrand	Doctorate Degree
University of New England (Australia)	Masters Business Admin
Monash University	Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Gavin B. Samuels's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
PFIZER, INC.	Health Technology

Private companies	1
Quark Pharmaceuticals, Inc. Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA.	Health Technology